This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): Oral Factor Xa Inhibitor
Description: Amgen acquired Oral Factor Xa Inhibitor on August 13, 2004 through Amgen's acquisition of Tularik.
Eli Lilly is developing an oral anticoagulant that is being studied for its utility in “prevention and treatment of thrombotic diseases.”The anticoagulant marketplace is undergoing a renaissance, with products like Sanofi-Synthelabo and Organon’s Arixtra and AstraZeneca’s Exanta showing much promise. Arixtra is a marketed parenteral formulation that, like Lilly’s compound, targets factor Xa. Exanta is oral thrombin inhibitor approaching regulatory review. Factor Xa and thrombin are intimately related, and are compelling targets for anticoagulation. Behind Arixtra and Exanta, multiple compounds approach these targets by differing means, each hoping that their pharmacology leads to superior, or at least equivalent, clinical results. Although the market is competitive, Lilly’s compound may prove to be complementary to marketed drugs. Even for a single patient, parenteral anticoagulation frequently gives way to oral anticoagulation as patients move from inpatient to outpatient settings. The reverse is also true.
Deal Structure: Eli Lilly designed this small molecule inhibitor of Factor Xa using Tulariks computer-aided molecular design (CAMD) in-silico drug discovery technology. Tularik will receive milestones and royalties.
Partners: Amgen, Inc.
Additional information available to subscribers only: